

# Algernon Pharmaceuticals Inc.

09:50 02 Apr 2020

## Algernon Pharmaceuticals finalizes protocol to launch Phase 2 trial of Ifenprodil for coronavirus patients

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) said it has finalized the protocol for a Phase 2 clinical study of its drug NP-120 (Ifenprodil) for coronavirus (COVID-19) patients in South Korea.

All ethics submission documents related to the study are near completion, the company said, and submission of the study for approval is expected to occur soon.

"We have been advised by our regulatory experts that submissions for ethics approval for COVID-19 related human trials are being reviewed on an expedited basis in most jurisdictions," CEO Christopher Moreau said in a statement.

### WATCH: Algernon Pharmaceuticals finding new uses for safe, older drugs

The study will be supported by Algernon and Novotech, a contract research organization (CRO) known for its work in Australia, New Zealand, South Africa and Asia.

Algernon also contracted Novotech for a second Phase 2 study of Ifenprodil to treat coronavirus patients in Australia, which the company will sponsor.

The decision to move forward with a second trial was based on the success of a recent feasibility study, the company said, and the ethics approval submission forms for the study are currently being prepared

"The Algernon and Novotech clinical development teams have worked tirelessly on the company's COVID-19 clinical trial program and have compressed processes that usually take many months, into days and weeks," Moreau said.

Algernon, based in Vancouver, is a drug repurposing company that investigates safe, already approved drugs for new disease applications. The company has filed new intellectual property rights around the world for Ifenprodil for the treatment of respiratory diseases and is working to develop a proprietary injectible, slow-release formulation.


Contact Andrew Kessel at [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter @andrew\_kessel

**Price:** 0.26

**Market Cap:** \$23.41 m

### 1 Year Share Price Graph



### Share Information

**Code:** AGN

**Listing:** CSE

**52 week High Low**  
0.58 0.04

**Sector:** Pharma & Biotech

**Website:** [algernonpharmaceuticals.com](http://algernonpharmaceuticals.com)

### Company Synopsis:

Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on the areas of non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). Algernon's key compounds were identified using a drug repurposing strategy.

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.